Ihc – Single Marker

2,000.00

Categories: ,

The IHC – Single Marker test refers to the use of Immunohistochemistry (IHC) to detect the presence or absence of one specific protein (marker) in a tissue sample. This test uses antibodies that bind to the targeted protein to help determine the tissue’s origin, type of cells involved, or disease state.
Common single markers tested include:
• ER/PR in breast cancer (estrogen/progesterone receptors)
• HER2/neu in breast or gastric cancers
• CD markers in lymphomas and leukemias
• Ki-67 for assessing tumor proliferation
• P53, CK, TTF-1, etc., depending on clinical suspicion

Description

Why It’s Done:
The test is performed to:
• Identify or confirm a diagnosis by detecting a specific protein.
• Classify tumors (e.g., carcinoma, lymphoma, sarcoma).
• Guide treatment decisions, especially when the protein is a target for therapy (e.g., HER2).
• Evaluate prognosis (some markers correlate with aggressive or slow-growing disease).
• Monitor recurrence or response to therapy in certain cases.

Preparation:
• Sample required: A tissue biopsy or surgical specimen.
• No patient preparation (such as fasting) is required.
• The sample is processed in the lab using a targeted antibody specific to the marker requested by the clinician.
• A detailed clinical history and provisional diagnosis should be shared with the lab to ensure appropriate marker selection and interpretation.